These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 22030098)

  • 21. Mitochondrial fatty acid beta-oxidation in the human eye and brain: implications for the retinopathy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
    Tyni T; Paetau A; Strauss AW; Middleton B; Kivelä T
    Pediatr Res; 2004 Nov; 56(5):744-50. PubMed ID: 15347768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Muscle MRI in patients with long-chain fatty acid oxidation disorders.
    Diekman EF; van der Pol WL; Nievelstein RA; Houten SM; Wijburg FA; Visser G
    J Inherit Metab Dis; 2014 May; 37(3):405-13. PubMed ID: 24305961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety of Lipistart, a medium-chain triglyceride based formula, in the dietary treatment of long-chain fatty acid disorders: a phase I study.
    MacDonald A; Webster R; Whitlock M; Gerrard A; Daly A; Preece MA; Evans S; Ashmore C; Chakrapani A; Vijay S; Santra S
    J Pediatr Endocrinol Metab; 2018 Mar; 31(3):297-304. PubMed ID: 29425111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood cytokine patterns suggest a modest inflammation phenotype in subjects with long-chain fatty acid oxidation disorders.
    McCoin CS; Gillingham MB; Knotts TA; Vockley J; Ono-Moore KD; Blackburn ML; Norman JE; Adams SH
    Physiol Rep; 2019 Mar; 7(6):e14037. PubMed ID: 30912279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment.
    Vockley J; Burton B; Berry GT; Longo N; Phillips J; Sanchez-Valle A; Tanpaiboon P; Grunewald S; Murphy E; Humphrey R; Mayhew J; Bowden A; Zhang L; Cataldo J; Marsden DL; Kakkis E
    Mol Genet Metab; 2017 Apr; 120(4):370-377. PubMed ID: 28189603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-chain 3-hydroxy fatty acids accumulating in long-chain 3-hydroxyacyl-CoA dehydrogenase and mitochondrial trifunctional protein deficiencies uncouple oxidative phosphorylation in heart mitochondria.
    Tonin AM; Amaral AU; Busanello EN; Grings M; Castilho RF; Wajner M
    J Bioenerg Biomembr; 2013 Feb; 45(1-2):47-57. PubMed ID: 23065309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variability in the clinical management of fatty acid oxidation disorders: results of a survey of Canadian metabolic physicians.
    Potter BK; Little J; Chakraborty P; Kronick JB; Evans J; Frei J; Sutherland SC; Wilson K; Wilson BJ
    J Inherit Metab Dis; 2012 Jan; 35(1):115-23. PubMed ID: 21630065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of mitochondrial long chain fatty acid oxidation and carnitine defects from a single center metabolic genetics clinic.
    Ambrose A; Sheehan M; Bahl S; Athey T; Ghai-Jain S; Chan A; Mercimek-Andrews S
    Orphanet J Rare Dis; 2022 Sep; 17(1):360. PubMed ID: 36109795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients with medium-chain acyl-coenzyme a dehydrogenase deficiency have impaired oxidation of fat during exercise but no effect of L-carnitine supplementation.
    Madsen KL; Preisler N; Orngreen MC; Andersen SP; Olesen JH; Lund AM; Vissing J
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1667-75. PubMed ID: 23426616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of dietary fatty acid chain-length on metabolic tolerance in mouse models of inherited defects in mitochondrial fatty acid beta-oxidation.
    Schuler AM; Gower BA; Matern D; Rinaldo P; Wood PA
    Mol Genet Metab; 2004 Dec; 83(4):322-9. PubMed ID: 15589119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The fate of medium-chain fatty acids in very long-chain acyl‑CoA dehydrogenase deficiency (VLCADD): A matter of sex?
    Wehbe Z; Alatibi K; Jellusova J; Spiekerkoetter U; Tucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Nov; 1864(11):1591-1605. PubMed ID: 31394165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disrupted fat distribution and composition due to medium-chain triglycerides in mice with a β-oxidation defect.
    Tucci S; Flögel U; Sturm M; Borsch E; Spiekerkoetter U
    Am J Clin Nutr; 2011 Aug; 94(2):439-49. PubMed ID: 21697078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of valinomycin in fibroblasts from patients with fatty acid oxidation disorders.
    Ndukwe Erlingsson UC; Iacobazzi F; Liu A; Ardon O; Pasquali M; Longo N
    Biochem Biophys Res Commun; 2013 Aug; 437(4):637-41. PubMed ID: 23867825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fasting-induced oxidative stress in very long chain acyl-CoA dehydrogenase-deficient mice.
    Tucci S; Primassin S; Spiekerkoetter U
    FEBS J; 2010 Nov; 277(22):4699-708. PubMed ID: 20883455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop.
    Spiekerkoetter U; Lindner M; Santer R; Grotzke M; Baumgartner MR; Boehles H; Das A; Haase C; Hennermann JB; Karall D; de Klerk H; Knerr I; Koch HG; Plecko B; Röschinger W; Schwab KO; Scheible D; Wijburg FA; Zschocke J; Mayatepek E; Wendel U
    J Inherit Metab Dis; 2009 Aug; 32(4):488-97. PubMed ID: 19399638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of heat stress and bezafibrate on mitochondrial beta-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay.
    Li H; Fukuda S; Hasegawa Y; Kobayashi H; Purevsuren J; Mushimoto Y; Yamaguchi S
    Brain Dev; 2010 May; 32(5):362-70. PubMed ID: 19589653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered Energetics of Exercise Explain Risk of Rhabdomyolysis in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency.
    Diekman EF; Visser G; Schmitz JP; Nievelstein RA; de Sain-van der Velden M; Wardrop M; Van der Pol WL; Houten SM; van Riel NA; Takken T; Jeneson JA
    PLoS One; 2016; 11(2):e0147818. PubMed ID: 26881790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
    Djouadi F; Aubey F; Schlemmer D; Ruiter JP; Wanders RJ; Strauss AW; Bastin J
    Hum Mol Genet; 2005 Sep; 14(18):2695-703. PubMed ID: 16115821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accumulation of 3-hydroxy-fatty acids in the culture medium of long-chain L-3-hydroxyacyl CoA dehydrogenase (LCHAD) and mitochondrial trifunctional protein-deficient skin fibroblasts: implications for medium chain triglyceride dietary treatment of LCHAD deficiency.
    Jones PM; Butt Y; Bennett MJ
    Pediatr Res; 2003 May; 53(5):783-7. PubMed ID: 12621125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substrate kinetics in patients with disorders of skeletal muscle metabolism.
    Ørngreen MC
    Dan Med J; 2016 Jul; 63(7):. PubMed ID: 27399985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.